Clinical Trials Browser

Denosumab × Genitourinary × Clear all

NCT03869762 2026-04-13

DICE

Phase 2 Terminated

Neoplasm Metastasis, Prostatic Neoplasms

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Phase 3 Active not recruiting

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT07043608 2025-07-02

ZAMBONI

Phase 2 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03280667 2023-03-29

KEYPAD

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

NCT03408652 2021-10-22

MOSCAR

Phase 3 Terminated

Carcinoma, Renal Cell

NCT02721433 2020-12-02

REaCT-BTA

Phase 4 Completed

BreastGenitourinary

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

NCT02758132 2019-11-08

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

Phase 2 Terminated

1 enrolled 7 charts

Prostatic Neoplasms

NCT01419717 2019-09-24

Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

Phase 3 Completed

129 enrolled 10 charts

BreastGenitourinary

Breast Neoplasms, Neoplasms, Prostatic Neoplasms

NCT00838201 2018-10-18

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Phase 3 Completed

384 enrolled 8 charts

Carcinoma, Neoplasms, Prostatic Neoplasms

NCT00089674 2018-10-17

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Phase 3 Completed

1,468 enrolled 24 charts

Prostatic Neoplasms

NCT00286091 2018-10-17

Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Phase 3 Completed

1,435 enrolled 15 charts

Hormone Refractory Prostate Cancer

NCT00896454 2018-10-17

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Phase 2 Completed

33 enrolled 22 charts

BreastGastrointestinalGenitourinaryHead & NeckLymphoidPlasma cellThoracic

Humoral Hypercalcemia Of Malignancy, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Hodgkin Disease, Hypercalcemia, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Parathyroid Neoplasms, Thyroid Neoplasms

NCT00925600 2017-05-30

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Phase 3 Completed

769 enrolled 21 charts

Bone Diseases, Metabolic, Cataract, Neoplasms, Osteoporosis, Prostatic Neoplasms

NCT01824342 2015-03-05

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

Phase 3 Completed

18 enrolled 13 charts

Castrate-resistant Prostate Cancer

NCT00950911 2014-02-11

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Phase 3 Completed

35 enrolled 8 charts

BreastGenitourinaryPlasma cell

Breast Neoplasms, Multiple Myeloma, Neoplasms, Prostatic Neoplasms